Imbruvica logo

Menu

  • Home
  • Taking IMBRUVICA®

You Can Take IMBRUVICA® Anywhere

Once-a-day dosing1

Because IMBRUVICA® is an oral medication, you have the freedom to take it at home or wherever you may be. 

  • For CLL/SLL
    IMBRUVICA® is dosed once a day as either a single 420-mg tablet or three 140-mg capsules. 
  • For WM
    IMBRUVICA® is dosed once a day as either a single 420-mg tablet or three 140-mg capsules.
  • For previously treated cGVHD
    IMBRUVICA® is dosed once a day as either a single 420-mg tablet or three 140-mg capsules.
IMBRUVICA® tablets or capsules
  • For previously treated MZL
    IMBRUVICA® is dosed once a day as either a single 560-mg tablet or four 140-mg capsules.
  • For previously treated MCL
    IMBRUVICA® is dosed once a day as either a single 560-mg tablet or four 140-mg capsules.

Talk to your doctor about which dosing option is right for you.

IMBRUVICA® tablets or capsules

Have questions about IMBRUVICA®?

Call us at 1-877-877-3536, or click here to learn more.

Learn More

Tablets and capsules are not shown at actual size.

    Taking IMBRUVICA® tablets1

    How to take IMBRUVICA® tablets

    • Take one IMBRUVICA® tablet by mouth, at about the same time each day, with a glass of water.
       

    About the IMBRUVICA® tablets blister pack

    • It contains 28 tablets (a 4-week supply)
    • Each tablet is identical
    • Blister packs are available in different tablet strengths. Contact your doctor for dosing instructions.

    IMBRUVICA® tablets come in a blister pack

    Taking IMBRUVICA® capsules1

    How to take IMBRUVICA® capsules

    • Take your dose of IMBRUVICA® capsules by mouth, at about the same time each day, with a glass of water
       

    About the IMBRUVICA® capsules bottles

    • The bottles contain a 30-day supply based on recommended dosing
    • Each capsule is identical

    IMBRUVICA® capsules come in a bottle

    • Do not open, break, or chew capsules.
    • Do not cut, crush, or chew tablets.
    • If you miss a dose of IMBRUVICA®, take it as soon as you remember on the same day
      • Take your next dose of IMBRUVICA® at your regular time on the next day
      • Do not take extra doses of IMBRUVICA® to make up for a missed dose
    • If you take too much IMBRUVICA®, call your healthcare provider or go to the nearest hospital emergency room right away
    • Call your doctor or pharmacist if you have any questions

    Tell your doctor about any other medications you are taking, including prescriptions or over-the-counter medications, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

    Store IMBRUVICA® in its original container at room temperature from 68°F to 77°F
    (20°C to 25°C).

    While taking IMBRUVICA®1

    • Do not drink grapefruit juice
    • Do not eat grapefruit
    • Do not eat Seville oranges, often used in marmalade

    These products may increase the amount of IMBRUVICA® in your blood.

    Strategies to help you plan your IMBRUVICA® routine2-6

    It’s important to take your medicines exactly as directed by your doctor.
    Creating a routine can help you remember. This will help you get the most
    benefit from your treatment.
     

    Link it. Take your medicine at the same time as something else you do on a daily basis, like walking the dog or brushing your teeth.

    See it. Use reminder notes or put your IMBRUVICA® container in a place you will see it (like next to your bed). Keep IMBRUVICA® out of the reach of children.

    Hear it. Set a daily alarm on your phone, watch, or clock to go off when you need to take IMBRUVICA®.

    Use your tools. Use tools, such as an app on your smartphone, or a calendar, to set reminders for yourself.

    Do not stop taking IMBRUVICA® without talking to your doctor. Always take IMBRUVICA® exactly as your doctor prescribes.

    Below you will see a tool you can use to remind you to take your IMBRUVICA® medication once a day, at about the same time every day. Remember to always take your medication exactly as your doctor has prescribed.

    Medisafe for IMBRUVICA®

    This free smartphone app for iOS or Android can remind you to take IMBRUVICA® exactly as your doctor prescribed. You can sign up to receive customized IMBRUVICA® information, too.

    Learn More About the Medisafe App
    Medisafe

    References:

    1. IMBRUVICA® (ibrutinib) Prescribing Information. Pharmacyclics LLC. 2019. 
    2. Borgsteede SD, Westerman MJ, Kok IL, Meeuse JC, de Vries TPGM, Hugtenburg JG. Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. Int J Clin Pharm. 2011;33(5):779-787. 
    3. National Institutes of Health MedlinePlus. Taking medicine at home—create a routine. http://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000613.htm. Published August 25, 2012. Accessed May 7, 2019.
    4. Ruppar TM, Russell CL. Medication adherence in successful kidney transplant recipients. Prog Transplant. 2009;19(2):167-172. 
    5. Tong A, Howell M, Wong G, Webster AC, Howard K, Craig JC. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant. 2011;26(1):344-354. 
    6. Ryan GW, Wagner GJ. Pill taking "routinization": a critical factor to understanding episodic medication adherence. AIDS Care. 2003;15(6):795-806.

    IMPORTANT SIDE EFFECT INFORMATION

    Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

    • have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
    • have bleeding problems.
    • have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes.
    • have an infection.
    • have liver problems.
    • are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®.
      • Females should not become pregnant during treatment and for 1 month after the last dose of IMBRUVICA®.
      • Males should avoid getting female partners pregnant during treatment and for 1 month after the last dose of IMBRUVICA®.
    • are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA® or breastfeed.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

    How should I take IMBRUVICA®?

    • Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
    • Take IMBRUVICA® 1 time a day.
    • Swallow IMBRUVICA® capsules and tablets whole with a glass of water.
    • Do not open, break, or chew IMBRUVICA® capsules.
    • Do not cut, crush, or chew IMBRUVICA® tablets.
    • Take IMBRUVICA® at about the same time each day.
    • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
    • If you take too much IMBRUVICA®, call your healthcare provider or go to the nearest hospital emergency room right away.

    What should I avoid while taking IMBRUVICA®?

    • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood

    What are the possible side effects of IMBRUVICA®?

    IMBRUVICA® may cause serious side effects, including:

    • Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time.
    • Infections can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
    • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
    • Heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter). Serious heart rhythm problems and death have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do a test to check your heart (ECG) and may change your IMBRUVICA® dose.
    • High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
    • Second primary cancers. New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
    • Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:

    • diarrhea
    • muscle and bone pain
    • rash
    • bruising
    • nausea
    • tiredness
    • fever

    The most common side effects of IMBRUVICA® in adults with cGVHD include:

    • tiredness
    • bruising
    • diarrhea
    • mouth sores (stomatitis)
    • muscle spasms
    • nausea
    • pneumonia

    Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

    These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    General information about the safe and effective use of IMBRUVICA®

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

    Please see the full Important Product Information.

    INDICATIONS

    What is IMBRUVICA® (ibrutinib)?

    IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with:

    • Mantle cell lymphoma (MCL) who have received at least one prior treatment
    • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
    • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
    • Waldenström's macroglobulinemia (WM)
    • Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
    • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy 

    It is not known if IMBRUVICA® is safe and effective in children.

    IMPORTANT SIDE EFFECT INFORMATION

    INDICATIONS